PACB · Pacific Biosciences Of California, Inc.
$2.41
+0.04 (+1.48%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$503.55M
Shares
310.83M
Volume · Oct 1
4.97M
Avg daily vol (3M)
8.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.37
Open$1.84
Day$1.84–2.46
52W close$1.11–2.67
Avg vol 30d9.8M
Short int48.9M · 15.7% float · 10.5d
Short vol39%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$159.27M
Trailing 12 months
Net income (TTM)
−$131.39M
Trailing 12 months
Revenue growth YoY
-1.9%
Year over year
Operating margin
-83.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.5%
Year over year · more shares
Price change (1Y)
+85.2%
Trailing year
Short interest
15.7%
Latest settlement · 10.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+51%
above
Price vs 50-day avg
+72%
above
RSI (14)
85
overbought
MACD trend
Positive
52-week position
81%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+85%
trailing
6-month return
+76%
trailing
YTD return
+27%
this year
Relative strength
+63%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +24 funds added
Insider flow
Distributing
Net -$30.4K over 90 days · 100% sells
Short interest
Falling
15.73% of float · ▼ -1.4% MoM · 10.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
223 holders — mid 3-yr range
Squeeze score
100
high risk · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
Gross margin
49%
expanding
EPS growth
−14%
Y/Y
Free cash flow
$-113.9M
Balance sheet
$571.6M
net debt
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Revenue
· full year 2026
Initiated
$155M – $165M
prior FY $160.01M
midpoint −0.0% Y/Y
Guided vs delivered
· last 2 settled
2024 revenue
2024
guided $170M – $200M
$154.01M
Miss −16.7%
Annual revenue
full year 2021
guided $128M – $132M
$130.51M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+51%
Bullish
Price vs 50-day avg
+72%
Bullish
RSI (14)
85
Bearish
MACD trend
Positive
Bullish
52-week position
81%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +24 funds added
Insider flow
Distributing
Net -$30.4K over 90 days · 100% sells
Short interest
Falling
15.73% of float · ▼ -1.4% MoM · 10.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
223 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 81%
Range high $3
vs 200-day avg +51%
vs 50-day avg +72%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Revio units sold | 20 | the three months ended June 30, 2026 filing | — |
| Vega units sold | 26 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PACB
this stock
Pacific Biosciences Of California, Inc.
|
$503.55M | +26.7% | +3.0% | — | 15.7% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PACB | +68.1% | +85.2% | +75.6% | +74.9% | +26.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +68.8% | +85.1% | +63.4% | +75.5% | +14.9% |